Beam Therapeutics Inc. (BEAM) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "BEAM"
      ],
      "issuer_cik": "0001745999",
      "owner_cik": "0001786304",
      "accession_number": "0001193125-26-424421",
      "form_type": "4",
      "filing_date": "2026-10-16",
      "period_of_report": "2026-10-15",
      "issuer_name": "Beam Therapeutics Inc.",
      "issuer_trading_symbol": "BEAM",
      "owner_name": "Evans John M.",
      "is_director": true,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "CEO",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-16",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 25000,
      "transaction_price_per_share": 23.9838,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 1047205,
      "transaction_value": 599595,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2026."
        },
        {
          "id": "F3",
          "description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.66 to $24.56, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."
        }
      ]
    },
    {
      "tickers": [
        "BEAM"
      ],
      "issuer_cik": "0001745999",
      "owner_cik": "0001786304",
      "accession_number": "0001193125-26-424421",
      "form_type": "4",
      "filing_date": "2026-10-16",
      "period_of_report": "2026-10-15",
      "issuer_name": "Beam Therapeutics Inc.",
      "issuer_trading_symbol": "BEAM",
      "owner_name": "Evans John M.",
      "is_director": true,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "CEO",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-15",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 25000,
      "transaction_price_per_share": 23.566,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 1047205,
      "transaction_value": 589150,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2026."
        },
        {
          "id": "F2",
          "description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.23 to $23.84, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. (\"BEAM\"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.